George Adams

Corvita Corporation is a development stage company engaged primarily in research and development of new medical devices and related biomaterials for treatment of late stage vascular disease. The company is sponsoring two FDA controlled, randomized prospective trials in the US for its peripheral grafts and AV access grafts, both of which are approved for sale in the European Common Market. In addition, Corvita is conducting clinical tests in Europe and plans to begin FDA controlled clinical studies in the US of the Corvita Endoluminal Graft, a new less invasive product for lower cost treatment of vascular trauma, vascular occlusive disease and aneurysmal disease. The majority of the company's activities in FY 96 will be focused on development and testing of Corvita Endoluminal Grafts.

EIDP, Inc. engages in the provision of science-based products and services. It operates through the Seed and Crop Protection segments. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms around the world. The Crop Protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that improve overall crop health both above and below ground via nitrogen management and seed-applied technologies. The company was founded by Eleuthere Irenee du Pont in 1802 and is headquartered in Indianapolis, IN.

World Heart Corp. develops artificial heart and related technologies. The company was founded on April 1, 1996 and is headquartered in Salt Lake City, UT.